Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease

Trial Profile

Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Pharmacokinetics
  • Sponsors Vtesse
  • Most Recent Events

    • 10 Aug 2017 Safety and efficacy results published in The Lancet.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Apr 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top